Circular RNA technology continues to demonstrate broad capability to significantly boost protein expression level and durability for both viral and non-viral gene and cell therapy, according to new data. 

Circio Holding shared the new and strengthened in vivo data for its circVec platform at the American Society of Gene and Cell Therapy (ASGCT) annual meeting 2025 in New Orleans, USA. 

In a poster presentation, Circio showcased its latest in vitro and in vivo results, which show that both viral and non-viral circVec vectors display tissue patterns that are distinct from equivalent mRNA-vectors.  

The pattern is hallmarked by increased protein expression in muscle, heart and spleen, and consistently low in liver.  

These observations demonstrate a fundamental biological difference between circRNA and mRNA-based expression and show that the circVec platform has advantages that can open new therapeutic opportunities where current gene therapy approaches fall short.  

“It has become evident that circVec not only offers increased protein expression level and durability in general, but also that this effect is associated with a distinct tissue profile. These results provide a valuable roadmap to direct our R&D activities and develop a therapeutic strategy focused on areas that are not well served by existing gene therapy approaches,” said Dr Thomas Hansen, CTO of Circio. 

In addition, Circio is continuing to progress its circVec-AAV gene therapy development for muscular dystrophies and cardiomyopathies. Longitudinal in vivo data up to six months show a general overall advantage of circVec expression at low dose levels.  

Enhanced target tissue expression and reduced liver accumulation is also observable with circVec-AAV vectors, indicating that the circVec advantage is more pronounced in specific tissues and therapeutic settings.  

Follow-up analyses and testing of novel circVec-AAV variants are currently ongoing to further explore these observations and identify the most favorable opportunities for circVec-AAV gene therapy development.

Diana Spencer, Senior Digital Content Editor, DDW